Post Profile






Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

(European Society for Medical Oncology) The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM). The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.
read more

share

Related Posts


Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, rese...

Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Tesaro ovarian cancer drug shows broad benefits in study

Health : Reuters: Health

COPENHAGEN (Reuters) - Tesaro's experimental drug niraparib improved outcomes for a broad range of women with recurrent ovarian cancer in a clinical study, boosting prospects for the product, which belongs to a closely watched class...

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Health : EurekAlert: Health

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the fir...

Comments


Copyright © 2016 Regator, LLC